|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified 497 patients with PMCTs, including angiosarcomas (27.3%) and Non-Hodgkin's lymphomas [NHL] (26.9%).
|
29414429 |
2018 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In Phase III, this was tested in 337 patients from five European countries and resulted in a questionnaire with 27 items for HL (EORTC QLQ-HL27), 29 items for HG-NHL (EORTC QLQ-NHL-HG29), 20 items for LG-NHL (EORTC QLQ-NHL-LG20) and 17 items for CLL (EORTC QLQ-CLL17).
|
29127596 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allogeneic HCT for lymphoid malignancies vary in trend with increases for NHL and decreases for Hodgkin lymphoma and myeloma.
|
29540849 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The analysis included 231 patients (66 ± 12 years old) suffering from multiple myeloma (MM) (N = 64), chronic lymphoid leukemia (CLL) (N = 84), aggressive non-Hodgkin B-cell lymphoma (aNHL) (N = 32), indolent NHL (N = 39), acute leukemia (N = 6), and Hodgkin disease (N = 6).
|
29644723 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The preliminary cytodiagnoses in 11 cases of chest wall lymphoid neoplasms were anaplastic large cell lymphoma (ALCL) in two cases, and ALCL/malignant melanoma, ALCL/T-cell-rich-B-cell lymphoma (TCRBCL)/Hodgkin's lymphoma (HL), plasmacytoma/neuroendocrine carcinoma, Hodgkin's lymphoma, small cell NHL/CLL, NHL, suggestive of NHL, post-transplant peripheral T-cell lymphoma (PTCL), and a malignant plasma cell tumour in one case each.
|
28730684 |
2017 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of clonality gene rearrangements in IGK and IGL genes using BIOMED-2 protocols could be implemented as a valuable method for improving clonality detection rate in HL cases and sensitivity (94%) and accuracy of HL diagnosis similar to that of the NHL samples will be increased.
|
26183240 |
2016 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotype distributions were studied in 213 lymphoma Caucasian patients (193 non-Hodgkin/NHL and 20 Hodgkin lymphoma/HL) and 214 controls, residents in a region of Southeast Spain.
|
23818366 |
2013 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used a panel of 193 formalin fixed tissues of lymphoma cases consisting of 55 cases of HL and 138 cases on several B-NHL entities.
|
22672495 |
2012 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This hypothesis was tested using various CD80(+) Burkitt B-NHL (non-Hodgkin lymphomas) cell lines as models.
|
22267549 |
2012 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This frequency was again highest for CLL, at 13.3% of CLL probands, compared to 8.8% of NHL probands and 5.9% of HL probands (P = 0.002).
|
18729853 |
2008 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings raise interesting possibilities about the role of signaling pathways triggered by membrane associated serine proteases in HL and aggressive NHL, similar to those described in epithelial tumors.
|
18179710 |
2008 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of non-Hodgkin lymphomas of B-cell type (B-NHL) exhibit chromosomal abnormalities including many types of reciprocal translocations closely related to specific histopathologic entities.
|
12885465 |
2003 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, gains and amplifications of the same region of chromosome 2p13 have been reported in 20% of extranodal B-cell non-Hodgkin lymphomas (B-NHL), in follicular and mediastinal B-NHL, and in Hodgkin disease (HD).
|
11719382 |
2001 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, NPM/ALK transcripts were not detected in any of the 34 cases of HD or in the 19 cases of T-NHL.
|
7662979 |
1995 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine if CDKN2 or another closely related gene on 9p is the target of 9p deletions in ALL and other hematologic malignancies, we analyzed 20 primary patient samples (13 ALL, 2 acute myeloid leukemias [AML], and 5 non-Hodgkin's lymphomas [NHL]) with 9p rearrangements using Southern blot analysis, fluorescence in situ hybridization (FISH), and single-strand conformation polymorphism (SSCP) for alterations of CDKN2.
|
7544647 |
1995 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
PCNA expression was high in neoplastic cells (> 50%) and variable (5-40%) in reactive lymphocytes in both HD and HD-like NHL. p53 positivity was found in RS cells and their variants in 64% of HD cases, but only in 25% of cases of HD-like NHL.
|
7833007 |
1994 |